● Developing story
Antimicrobial resistance tracker 2025-26: data, drugs and policy
WHO reported in October 2025 that one in six lab-confirmed bacterial infections in 2023 were resistant, and that resistance rose in over 40% of the combinations it tracks.[1][2] In May 2026 the World Health Assembly adopted an updated Global Action Plan on AMR for 2026–2036.[3] The 5th global ministerial conference on AMR, postponed from June, is now scheduled for 6–8 December 2026 in Abuja, Nigeria.[4]
What we know
- About one in six lab-confirmed bacterial infections in 2023 were resistant to antibiotics[1]
- Resistance rose in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023[2]
- The clinical antibacterial pipeline shrank from 97 agents in 2023 to 90 in 2025[14]
- The FDA approved two new oral gonorrhea antibiotics in December 2025[17]
- The updated Global Action Plan on AMR 2026-2036 was adopted by the World Health Assembly on 23 May 2026[3]
- The Abuja ministerial conference is scheduled for 6-8 December 2026[4]
- CDC's 2026 threats report estimates more than 9.3 million drug-resistant infections a year in the US[13]
What we don't know yet
- What the Abuja conference will adopt, and whether the final Abuja Compact includes financing commitments
- Whether the Independent Panel on Evidence for Action against AMR is launched in Abuja as planned
- Whether FAO and UNEP formally endorse the updated Global Action Plan through their own governing bodies
- Whether the PASTEUR Act gets a committee or floor vote in the current Congress
- Whether countries are on track for the 2030 target of a 10% cut in AMR-associated deaths
This tracker logs dated developments in antimicrobial resistance from October 2025 to 7 November 2026, from WHO, the Quadripartite, regulators and specialist news outlets. It is not medical advice; talk to a clinician about any infection or treatment. For background, read antibiotic resistance explained and how new antibiotics are developed.
WHO data published in 2025 showed resistance still rising, and in 2026 governments adopted a new global plan to tackle it.[2][3] The next milestone is the 5th Global High-Level Ministerial Conference on AMR, now scheduled for 6–8 December 2026 in Abuja.[4]
The background: the 2024 UN declaration
In September 2024 the UN General Assembly adopted a political declaration on AMR.[5] Its headline target is to cut the estimated 4.95 million annual deaths associated with bacterial AMR by 10% by 2030.[5] It also called for US$100 million in catalytic funding so that at least 60% of countries have funded national action plans by 2030.[6] The declaration asked the Quadripartite (FAO, UNEP, WHO and WOAH) to update the Global Action Plan on AMR by 2026 and to set up an independent evidence panel.[7] The 2026 action plan and the planned evidence panel answer those requests.[3][8]
New data: resistance keeps rising
WHO’s Global antibiotic resistance surveillance report 2025, released on 13 October 2025, drew on data from over 100 countries.[9] Its main findings:
- About one in six lab-confirmed bacterial infections in 2023 were resistant to antibiotics.[1]
- Between 2018 and 2023, resistance rose in over 40% of monitored pathogen–antibiotic combinations, by 5–15% a year on average.[2]
- Resistance was highest in WHO’s South-East Asia and Eastern Mediterranean regions, at 1 in 3 reported infections.[10]
- More than 40% of E. coli and over 55% of K. pneumoniae were resistant to third-generation cephalosporins.[11]
Reporting has grown, from 25 countries in 2016 to 104 in 2023, but 48% of countries did not report data in 2023.[12] In the United States, CDC’s 2026 threats report estimates more than 9.3 million drug-resistant infections and more than 39,000 deaths a year.[13]
New drugs and the pipeline
On 2 October 2025 WHO reported that the clinical antibacterial pipeline had shrunk from 97 agents in 2023 to 90, with only 15 judged innovative.[14][15] In March 2026 it published target product profiles to steer developers toward severe resistant infections and bacterial meningitis.[16]
In December 2025 the US FDA approved two oral antibiotics for uncomplicated urogenital gonorrhea: gepotidacin on 11 December and zoliflodacin on 12 December.[17] Zoliflodacin is a first-in-class antibiotic, the first developed solely for gonorrhea in decades.[18] The FDA said extra options matter given the global rise in drug-resistant gonorrhea.[18]
In the United States, five House members reintroduced an updated PASTEUR Act in February 2026, the bill’s fourth introduction.[19] It would create subscription-style payments for critically needed antibiotics and antifungals.[20]
A new global action plan
The World Organisation for Animal Health’s 183 members adopted the updated Global Action Plan on AMR 2026–2036 on 21 May 2026, the first Quadripartite body to do so.[21] Two days later, on 23 May, the 79th World Health Assembly adopted it, updating the original plan adopted in 2015.[3] By 2030 the plan aims to enable the UN target of a 10% cut in bacterial AMR-associated deaths, while reducing antimicrobial use in agrifood systems and environmental pollution.[22] It has six strategic objectives, from awareness and surveillance to research and financing.[23] Delegates stressed prevention first, including infection control, sanitation and vaccination.[24]
What’s next: the Abuja conference
The 5th Global High-Level Ministerial Conference on AMR was scheduled for 28–30 June 2026 in Abuja, Nigeria, but was postponed; it is now set for 6–8 December 2026.[4] The host and the Quadripartite are consulting on a draft outcome document, the Abuja Compact.[25] The Quadripartite plans to launch the Independent Panel on Evidence for Action against AMR at the conference.[8]
Still pending: the Abuja conference outcome and the evidence panel launch. This page will be updated after the conference.
Timeline
10 confirmed
confirmed
WHO updates its AMR fact sheet to reflect the new action plan[28][23]
confirmed
Abuja ministerial conference postponed[4]
The meeting had been scheduled for 28-30 June 2026. ReAct reported the postponement on 26 June.
confirmed
World Health Assembly adopts the Global Action Plan on AMR 2026-2036[3][22]
confirmed
WOAH members adopt the updated Global Action Plan[21]
WOAH was the first Quadripartite body to adopt the plan through its governing body.
confirmed
WHO publishes target product profiles for urgently needed antibiotics[16][27]
confirmed
Updated PASTEUR Act reintroduced in the US House[19][20]
The bill would pay developers of critically needed antibiotics and antifungals fixed annual amounts regardless of use.
confirmed
FDA approves zoliflodacin, a first-in-class gonorrhea antibiotic[17][18]
confirmed
FDA approves gepotidacin for gonorrhea[17][26]
Gepotidacin (Blujepa) was first approved in March 2025 for urinary tract infections.
confirmed
WHO surveillance report finds one in six infections resistant[1][2][9]
Data from over 100 countries showed resistance rising in over 40% of monitored pathogen-antibiotic combinations, by 5-15% a year.
confirmed
WHO finds the antibacterial pipeline shrinking[14][15]
Clinical candidates fell from 97 in 2023 to 90; only 15 count as innovative and only 5 target a critical priority pathogen.
Read next
You've reached the end of the course. Next crash course
Galleri (multi-cancer early detection blood test)
Galleri is GRAIL's blood test that screens for 50+ cancer types. How it works, NHS-Galleri and PATHFINDER 2 results, accuracy and FDA status in 2026.
Questions readers ask
What is the latest global data on antibiotic resistance?
WHO's 2025 surveillance report found that about one in six lab-confirmed bacterial infections in 2023 were resistant, and that resistance rose in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023.[1][2]
What is the Global Action Plan on AMR 2026-2036?
An updated global framework adopted by the World Health Assembly on 23 May 2026. By 2030 it aims to enable a 10% cut in bacterial AMR-associated deaths while reducing antimicrobial use in agrifood systems.[3][22]
When is the Abuja AMR ministerial conference?
It was scheduled for 28-30 June 2026 but was postponed. The Quadripartite Joint Secretariat now lists 6-8 December 2026 in Abuja, Nigeria.[4]
Were any new antibiotics approved recently?
Yes. In December 2025 the FDA approved two oral antibiotics for uncomplicated urogenital gonorrhea, gepotidacin and zoliflodacin.[17]
Sources
· 28 claims from 9 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
About one in six laboratory-confirmed bacterial infections worldwide in 2023 were resistant to antibiotic treatment, according to WHO's Global antibiotic resistance surveillance report 2025. confirmedas of 2025-10-13
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- Antimicrobial resistance (fact sheet) · World Health Organization · Primary source · 2026-07-16 (retrieved 2026-11-07)
- [2]
Between 2018 and 2023, antibiotic resistance rose in over 40% of the pathogen–antibiotic combinations WHO monitored, with an average annual increase of 5–15%. confirmedas of 2025-10-13
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- Antimicrobial resistance (fact sheet) · World Health Organization · Primary source · 2026-07-16 (retrieved 2026-11-07)
- [3]
On 23 May 2026 member states at the 79th World Health Assembly adopted the updated Global Action Plan on Antimicrobial Resistance for 2026–2036, which builds on the original plan adopted in 2015. confirmedas of 2026-05-25
- The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026–2036) · World Health Organization · Primary source · 2026-05-25 (retrieved 2026-11-07)
- The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026–2036) · World Health Organization · Primary source · 2026-05-25 (retrieved 2026-11-07)
- [4]
The 5th Global High-Level Ministerial Conference on AMR, originally scheduled for 28–30 June 2026 in Abuja, Nigeria, was postponed and is now scheduled for 6–8 December 2026. confirmedas of 2026-11-07
- Abuja meeting postponed: a moment to close the gaps before ministers reconvene · ReAct (Action on Antibiotic Resistance) · Secondary source · 2026-06-26 (retrieved 2026-11-07)
- 5th Global High-Level Ministerial Conference on Antimicrobial Resistance (AMR) · Quadripartite Joint Secretariat on AMR · Primary source (retrieved 2026-11-07)
- [5]
The political declaration on AMR adopted at the UN General Assembly in September 2024 commits countries to reduce the estimated 4.95 million annual deaths associated with bacterial AMR by 10% by 2030. confirmedas of 2024-09-26
- World leaders commit to decisive action on antimicrobial resistance · World Health Organization (joint Quadripartite release) · Primary source · 2024-09-26 (retrieved 2026-11-07)
- [6]
The 2024 declaration calls for US$100 million in catalytic funding to help at least 60% of countries have funded national AMR action plans by 2030. confirmedas of 2024-09-26
- World leaders commit to decisive action on antimicrobial resistance · World Health Organization (joint Quadripartite release) · Primary source · 2024-09-26 (retrieved 2026-11-07)
- [7]
The 2024 declaration asked the Quadripartite organisations (FAO, UNEP, WHO and WOAH) to update the Global Action Plan on AMR by 2026 and to establish an independent panel on evidence for action against AMR in 2025. confirmedas of 2024-09-26
- World leaders commit to decisive action on antimicrobial resistance · World Health Organization (joint Quadripartite release) · Primary source · 2024-09-26 (retrieved 2026-11-07)
- World leaders commit to decisive action on antimicrobial resistance · World Health Organization (joint Quadripartite release) · Primary source · 2024-09-26 (retrieved 2026-11-07)
- [8]
The Quadripartite plans to launch the Independent Panel on Evidence for Action against AMR at the 5th Global High-Level Ministerial Conference, after a UN member-state consultation on its draft founding document in December 2025. confirmedas of 2026-11-07
- Independent Panel on Evidence for Action against AMR, roadmap · Quadripartite Joint Secretariat on AMR · Primary source (retrieved 2026-11-07)
- Independent Panel on Evidence for Action against AMR, roadmap · Quadripartite Joint Secretariat on AMR · Primary source (retrieved 2026-11-07)
- [9]
The 2025 WHO surveillance report drew on data from over 100 countries and, for the first time, estimated resistance across 22 antibiotics and 8 common bacterial pathogens. confirmedas of 2025-10-13
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- [10]
WHO estimates resistance is highest in its South-East Asia and Eastern Mediterranean regions, where 1 in 3 reported infections were resistant, compared with 1 in 5 in the African Region. confirmedas of 2025-10-13
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- [11]
More than 40% of E. coli and over 55% of K. pneumoniae are now resistant globally to third-generation cephalosporins, the first-choice treatment for these infections, and resistance exceeds 70% in WHO's African Region. confirmedas of 2025-10-13
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- [12]
Country participation in WHO's GLASS surveillance system rose from 25 countries in 2016 to 104 in 2023, but 48% of countries did not report data in 2023. confirmedas of 2025-10-13
- WHO warns of widespread resistance to common antibiotics worldwide · World Health Organization · Primary source · 2025-10-13 (retrieved 2026-11-07)
- [13]
CDC's 2026 Antimicrobial Resistance Threats Report estimates more than 9.3 million drug-resistant infections and more than 39,000 resulting deaths in the United States each year. confirmedas of 2026-11-07
- About Antimicrobial Resistance · US Centers for Disease Control and Prevention · Primary source (retrieved 2026-11-07)
- [14]
WHO's 2025 pipeline analysis found the number of antibacterials in clinical development fell from 97 in 2023 to 90 in 2025, of which 50 are traditional antibacterial agents and 40 are non-traditional approaches such as bacteriophages and antibodies. confirmedas of 2025-10-02
- WHO releases new reports on new tests and treatments in development for bacterial infections · World Health Organization · Primary source · 2025-10-02 (retrieved 2026-11-07)
- [15]
Of the 90 antibacterials in clinical development, WHO counts only 15 as innovative and only 5 as effective against at least one of its "critical" priority bacteria. confirmedas of 2025-10-02
- WHO releases new reports on new tests and treatments in development for bacterial infections · World Health Organization · Primary source · 2025-10-02 (retrieved 2026-11-07)
- WHO releases new reports on new tests and treatments in development for bacterial infections · World Health Organization · Primary source · 2025-10-02 (retrieved 2026-11-07)
- [16]
In March 2026 WHO published target product profiles for new antibiotics against severe multidrug-resistant Gram-negative infections, resistant Gram-positive infections in immunosuppressed and critically ill patients, and bacterial meningitis. confirmedas of 2026-03-11
- WHO releases new target product profiles for urgently needed antibiotics · World Health Organization · Primary source · 2026-03-11 (retrieved 2026-11-07)
- [17]
The US FDA approved two new oral antibiotics for uncomplicated urogenital gonorrhea in December 2025, gepotidacin (Blujepa) on December 11 and zoliflodacin (Nuzolvence) on December 12. confirmedas of 2025-12-16
- FDA approves two oral therapies to treat gonorrhea · US Food and Drug Administration · Primary source · 2025-12-12 (retrieved 2026-11-07)
- FDA approves two oral therapies to treat gonorrhea · US Food and Drug Administration · Primary source · 2025-12-12 (retrieved 2026-11-07)
- FDA approves 2 new oral gonorrhea antibiotics · CIDRAP (University of Minnesota) · Secondary source · 2025-12-16 (retrieved 2026-11-07)
- [18]
Zoliflodacin is a first-in-class antibiotic, the first developed solely for gonorrhea in decades, developed through a public-private partnership between Innoviva Specialty Therapeutics and a nonprofit. confirmedas of 2025-12-16
- FDA approves 2 new oral gonorrhea antibiotics · CIDRAP (University of Minnesota) · Secondary source · 2025-12-16 (retrieved 2026-11-07)
- FDA approves two oral therapies to treat gonorrhea · US Food and Drug Administration · Primary source · 2025-12-12 (retrieved 2026-11-07)
- [19]
In early February 2026 five members of the US House, led by Buddy Carter with Scott Peters, Nick Langworthy, Mike Levin and Mike Carey, reintroduced an updated PASTEUR Act, its fourth introduction. confirmedas of 2026-02-09
- PASTEUR Act Reintroduced in Congress · Contagion Live · Secondary source · 2026-02-05 (retrieved 2026-11-07)
- Updated PASTEUR Act reintroduced in Congress to boost antibiotic development · CIDRAP (University of Minnesota) · Secondary source · 2026-02-09 (retrieved 2026-11-07)
- [20]
The proposed US PASTEUR Act would let the federal government sign subscription-style contracts paying developers of critically needed antibiotics and antifungals fixed annual amounts regardless of how often the drugs are used. confirmedas of 2026-02-09
- Updated PASTEUR Act reintroduced in Congress to boost antibiotic development · CIDRAP (University of Minnesota) · Secondary source · 2026-02-09 (retrieved 2026-11-07)
- PASTEUR Act Reintroduced in Congress · Contagion Live · Secondary source · 2026-02-05 (retrieved 2026-11-07)
- [21]
On 21 May 2026 the 183 Members of the World Organisation for Animal Health adopted the updated Global Action Plan on AMR 2026–2036, the first Quadripartite body to do so through its governing body. confirmedas of 2026-07-20
- WOAH Members adopt the updated Global Action Plan on Antimicrobial Resistance · World Organisation for Animal Health · Primary source · 2026-07-20 (retrieved 2026-11-07)
- WOAH Members adopt the updated Global Action Plan on Antimicrobial Resistance · World Organisation for Animal Health · Primary source · 2026-07-20 (retrieved 2026-11-07)
- [22]
By 2030 the 2026–2036 Global Action Plan aims to enable the UN target of a 10% reduction in bacterial AMR-associated deaths, while reducing antimicrobial use in agrifood systems and environmental pollution from resistant microbes and antimicrobial residues. confirmedas of 2026-11-07
- Antimicrobial resistance (fact sheet) · World Health Organization · Primary source · 2026-07-16 (retrieved 2026-11-07)
- [23]
The 2026–2036 plan has six strategic objectives, covering awareness, surveillance, infection prevention, access and appropriate use, research and innovation, and governance and financing. confirmedas of 2026-11-07
- Antimicrobial resistance (fact sheet) · World Health Organization · Primary source · 2026-07-16 (retrieved 2026-11-07)
- [24]
During the 2026 Assembly, delegates stressed prevention-first measures including infection prevention and control, water, sanitation and hygiene, vaccination and biosecurity. confirmedas of 2026-05-25
- The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026–2036) · World Health Organization · Primary source · 2026-05-25 (retrieved 2026-11-07)
- [25]
Ahead of the Abuja conference, the host and the Quadripartite are consulting member states and stakeholders on a draft outcome document, the Abuja Compact. confirmedas of 2026-11-07
- 5th Global High-Level Ministerial Conference on Antimicrobial Resistance (AMR) · Quadripartite Joint Secretariat on AMR · Primary source (retrieved 2026-11-07)
- [26]
Gepotidacin (Blujepa) was first approved by the FDA in March 2025 to treat urinary tract infections. confirmedas of 2025-12-16
- FDA approves two oral therapies to treat gonorrhea · US Food and Drug Administration · Primary source · 2025-12-12 (retrieved 2026-11-07)
- [27]
WHO said in March 2026 that, despite 90 new antibacterial agents in development, few clinical candidates target priority pathogens and even fewer are innovative. confirmedas of 2026-03-11
- WHO releases new target product profiles for urgently needed antibiotics · World Health Organization · Primary source · 2026-03-11 (retrieved 2026-11-07)
- [28]
WHO's fact sheet, updated in July 2026, says bacterial AMR was associated with more than 4.7 million deaths globally in 2021. confirmedas of 2026-07-16
- Antimicrobial resistance (fact sheet) · World Health Organization · Primary source · 2026-07-16 (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Dec 9, 2026.
Cite this page
"Antimicrobial resistance tracker 2025-26: data, drugs and policy." ContentLora, updated Nov 7, 2026. https://contentlora.com/events/antimicrobial-resistance-tracker
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.